What is the Frederickson classification of inherited lipoprotein disorders?

Fredrickson Classification of Lipoprotein Disorders

The Fredrickson classification (also known as Fredrickson-Levy-Lees classification) is a phenotypic system that categorizes inherited lipoprotein disorders into five main types (I, IIa, IIb, III, IV, and V) based on which lipoproteins are elevated, with important implications for cardiovascular risk and pancreatitis risk 1.

Classification System Overview

The classification is based on lipoprotein patterns identified through electrophoresis and ultracentrifugation, though simpler methods using cholesterol and triglyceride measurements can approximate these patterns 2. This system remains clinically relevant today, with modern studies showing that approximately 34% of the general population exhibits one of these phenotypes 3.

The Five Primary Phenotypes

Type I (Familial Chylomicronemia Syndrome)

• Lipoprotein pattern: Markedly elevated chylomicrons 1
• Lipid profile: TG typically >1000 mg/dL with TG-to-cholesterol ratio of 10:1 1
• Genetic basis: Autosomal recessive; caused by lipoprotein lipase (LPL) deficiency, apolipoprotein C-II deficiency, apolipoprotein A-V deficiency, or GPIHBP1 mutations 1
• Clinical features: Eruptive xanthomas, lipemia retinalis, hepatosplenomegaly, and high risk of acute pancreatitis 1
• Prevalence: Extremely rare (1 in 1,000) 1
• Cardiovascular risk: Generally believed to be low, though cases of CAD have been reported 1

Type IIa (Familial Hypercholesterolemia)

• Lipoprotein pattern: Elevated LDL cholesterol only 4
• Lipid profile: LDL-C ≥190 mg/dL in children or ≥250 mg/dL in adults without secondary causes 5
• Genetic basis: Mutations in LDLR, APOB, or PCSK9 genes 5
• Clinical features: Tendon xanthomas, corneal arcus, premature coronary artery disease 5
• Prevalence: 3.2-3.9% in modern populations 3
• Cardiovascular risk: Very high; major risk factor for premature atherosclerosis 5

Type IIb (Combined Hyperlipidemia/FCHL)

• Lipoprotein pattern: Elevated LDL and VLDL 1
• Lipid profile: Elevated cholesterol, triglycerides (200-1000 mg/dL), and apolipoprotein B levels >90th percentile 1
• Genetic basis: Genetically complex, polygenic disorder with hepatic overproduction of apo B-containing lipoproteins 1
• Clinical features: Often associated with obesity, metabolic syndrome features; onset typically in adulthood 1
• Prevalence: Common (1-2% in white populations); 8-10% in modern studies 1, 3
• Cardiovascular risk: High; associated with premature CVD, especially with metabolic syndrome features 1

Type III (Dysbetalipoproteinemia)

• Lipoprotein pattern: Accumulation of chylomicron and VLDL remnants 1
• Lipid profile: Both TG and cholesterol elevated to approximately similar levels; characteristic VLDL-C to plasma TG ratio of ≥0.3 1
• Genetic basis: Autosomal recessive; requires apolipoprotein E2/E2 genotype (most common mutation: Arg158Cys) plus an acquired "second hit" for clinical expression 1
• Clinical features: Palmar xanthomas (pathognomonic), tuberous xanthomas, premature atherosclerosis 1
• Prevalence: Rare; 1.7-2.0% by modern apoB methods 6
• Cardiovascular risk: Very high; powerfully promotes premature cardiovascular disease if untreated 6

Type IV (Familial Hypertriglyceridemia)

• Lipoprotein pattern: Elevated VLDL only 1
• Lipid profile: TG 200-1000 mg/dL; apolipoprotein B levels NOT elevated (distinguishes from Type IIb) 1
• Genetic basis: Polygenic; VLDL overproduction and reduced VLDL catabolism resulting in LPL saturation 1
• Clinical features: Often not expressed until adulthood due to environmental factors, obesity, stress 1
• Prevalence: Common (5-10%); 20-24% in modern populations 1, 3
• Cardiovascular risk: Usually not associated with CHD unless metabolic syndrome features present or baseline TG >200 mg/dL 1

Type V (Mixed Hypertriglyceridemia)

• Lipoprotein pattern: Elevated VLDL and chylomicrons 1
• Lipid profile: TG can exceed 1000 mg/dL when secondary triggers occur 1
• Genetic basis: Heterozygous mutations in genes affecting TG metabolism (apoA-V, LPL) that require acquired secondary causes to manifest 1
• Clinical features: Risk of pancreatitis when TG >1000 mg/dL 1
• Prevalence: Rare (0.13-0.15%) 3
• Cardiovascular risk: Variable; premature atherosclerosis can occur 1

Clinical Significance and Risk Stratification

The phenotypes differ substantially in their association with atherosclerotic cardiovascular disease, with risk hierarchy: Type V > IIb > IV > IIa > normolipidemic 4. This risk stratification can be used as a risk enhancer condition in patient management 4.

Key Clinical Pitfalls

• Diabetes and obesity dramatically increase prevalence: Those with diabetes (51.6%) or obesity (49.0%) have much higher prevalence of these phenotypes compared to those without diabetes (31.3%) or normal BMI (18.3%) 3
• Age matters: Those aged 40-74 years have the highest overall prevalence 3
• Secondary causes must be excluded: Hypothyroidism, poorly controlled diabetes, pregnancy (especially third trimester), medications (estrogens, beta-blockers, steroids, thiazides, protease inhibitors), and alcohol excess can all trigger or worsen hypertriglyceridemia 1
• Type III requires high clinical suspicion: Look for approximately equal elevation of TG and cholesterol, palmar xanthomas, and VLDL-C/TG ratio ≥0.3 1

Modern Diagnostic Approach

The classification can now be determined using only the standard lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) without requiring advanced ultracentrifugation or electrophoresis 4. This makes the system far more accessible for routine clinical practice and increases compliance with current guidelines 4.